Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note released on Sunday. The firm issued a sell rating on the stock.

Separately, Alliance Global Partners boosted their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a buy rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

Shares of TNXP opened at $0.30 on Friday. Tonix Pharmaceuticals has a twelve month low of $0.29 and a twelve month high of $32.32. The stock’s 50 day moving average is $0.62 and its two-hundred day moving average is $4.89. The firm has a market capitalization of $896,397.20, a PE ratio of 0.00 and a beta of 2.12. The company has a current ratio of 1.15, a quick ratio of 0.87 and a debt-to-equity ratio of 0.13.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. Research analysts anticipate that Tonix Pharmaceuticals will post -34.73 earnings per share for the current year.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC lifted its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the period. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.